Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21022845 | 0.85 | SCN10A (0.34) | ESR1ESR2SCN10AKCNH2 | |
| SCHEMBL20374955 | 0.85 | SCN10A (0.35) | ESR1ESR2SCN10AKCNH2 | |
| SCHEMBL21650123 | 0.81 | NPC1 (0.38) | SCN10AKCNH2 | |
| SCHEMBL10261363 | 0.77 | SCN10A (0.47) | SCN10AKCNH2 | |
| SCHEMBL18687266 | 0.73 | CNR2 (0.35) | ESR1ESR2SCN10A | |
| SCHEMBL7855336 | 0.71 | METAP2 (0.49) | SCN10AKCNH2 | |
| SCHEMBL24960591 | 0.70 | ESR1 (0.37) | ESR1 | |
| SCHEMBL1023455 | 0.69 | NPC1 (0.38) | — | |
| SCHEMBL14208120 | 0.68 | CNR1 (0.39) | — | |
| SCHEMBL318089 | 0.67 | KIF11 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-19 | — | — | US | disclosed |
| US-9637505-B2 | 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides | DOW AGROSCIENCES LLC (US) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105503-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ESR1 2485/4885ESR2 2921/4885SCN10A 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.